Sabra Health Care REIT (SBRA) Insider Malehorn Buys 8,310 Shares

Insider Buying and Selling at Sabra Health Care REIT, Inc.

Jeffrey Malehorn joined a group of insiders picking up shares of Sabra Health Care REIT, Inc. (NasdaqGS: SBRA) on June 17, 2026. Form 4 filings with the SEC showed that Malehorn, alongside Craig Barbarosh, Michael Foster, Catherine Cusack, Lynne Katzmann, and Ann Kono, each acquired identical blocks of 8,310 shares on that date. These transactions followed earlier reported insider purchases from mid-June, continuing a pattern of internal acquisitions at the healthcare real estate investment trust.

Stock Price Positioning and Range

Trading near $18.12, the stock sits inside its 52-week trading band that stretches from a low of $17.17 up to a high of $22.77. Shares have moved below the 50-day moving average of $20.71 and the 200-day moving average of $19.93. The company carries a market capitalization of roughly $5.08 billion, with a forward P/E ratio of 24.53 based on upcoming profit estimates.

Recent Earnings Performance

Sabra Health Care REIT posted revenue of $863.77 million over the trailing period, alongside a revenue growth rate of 25.3%. The company generated earnings per share of $0.26, paired with a net margin of 7.58% and a return on equity of 2.39%. Investors can expect the next round of financial results when the company reports earnings on November 4, 2026.

Dividend Yield and Payouts

The real estate investment trust distributes an annual dividend rate of $1.20 per share, delivering a dividend yield of 6.04%. The payout ratio stands at 4.62%, indicating how much of the company's earnings go toward shareholder distributions.

Analysts Set New Price Targets

Wall Street firms have adjusted their views on the stock through recent months. On October 13, 2026, UBS maintained its Neutral rating while adjusting its price target to $20.00 from $21.00. On the same day, Barclays kept an Equal-Weight rating and moved its target to $21.00 from $23.00, following an earlier adjustment to $23.00 on August 31, 2026. Baird maintained a Neutral rating on August 31, 2026, with a $21.00 target. Raymond James upgraded the shares to Market Perform on August 6, 2026. Earlier in July, Truist Securities kept a Buy rating with a $24.00 target, and Citizens maintained a Market Outperform rating with a $25.00 target. Overall, the consensus recommendation sits at buy, backed by 14 analyst opinions pointing to a mean target price of $22.79.

Healthcare Real Estate Portfolio

Sabra Health Care REIT operates as a self-administered real estate investment trust owning properties that serve the healthcare sector across the United States and Canada. Based in Tustin, California, the company manages skilled nursing facilities, senior housing, and specialty hospitals through its subsidiaries.

What to Watch at Sabra Health Care REIT, Inc.

Market participants will be tracking upcoming SEC filings to see whether additional insiders expand their positions. The next major catalyst arrives on November 4, 2026, when the company releases its financial results for the quarter.